Earnings ·
Tempest Therapeutics reported second quarter 2026 financial results, posting a net loss of $5.2 million ($0.34 per…
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics reported second quarter 2026 financial results, posting a net loss of $5.2 million ($0.34 per share) compared to $7.9 million in the prior year period. Cash and cash equivalents decreased to $0.8 million from $7.7 million at year-end 2025, primarily due to one-time transaction costs associated with an February 2026 asset acquisition, offset by net proceeds of $1.7 million from a March private placement and $1.7 million from a warrant inducement in the second quarter. The company executed a development collaboration with Senlang Biotechnology for its CD7-targeted TPST-4003 candidate, with first patient dosing expected in Q4 2026. Additionally, Tempest appointed Drake Richey and John Yee to its Board of Directors and Andrew Fang as Head of Business Development. The company operates in the biotechnology industry, developing next-generation in vivo CAR-T therapies for oncology and autoimmune indications.